CHILDREN'S CLARITIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S CLARITIN (CHILDREN'S CLARITIN).
Loratadine is a long-acting second-generation antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby inhibiting the effects of histamine released from mast cells and basophils, reducing allergic symptoms.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6 to descarboethoxyloratadine; systemic exposure may increase with co-administration of CYP3A4 or CYP2D6 inhibitors. |
| Excretion | Loratadine is primarily eliminated via hepatic metabolism, with approximately 80% of the dose excreted as metabolites in urine (40%) and feces (40%). Less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life of loratadine is 8-14 hours (mean 11 hours) in healthy adults; for the active metabolite descarboethoxyloratadine, half-life is 17-24 hours (mean 20 hours). This supports once-daily dosing. |
| Protein binding | Loratadine is 97-99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The active metabolite is 73-76% bound. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is approximately 120 L/kg for loratadine and 7-12 L/kg for the active metabolite, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability of loratadine is approximately 40% due to extensive first-pass metabolism. The active metabolite is responsible for most of the clinical effect. |
| Onset of Action | Oral: Onset of symptom relief occurs within 1-3 hours after administration, with peak effect at 4-6 hours. |
| Duration of Action | Oral: Duration of action is at least 24 hours, allowing once-daily dosing. Clinical studies show sustained antihistamine effects for 24 hours. |
| Molecular Weight | 382.88 |
10 mg orally once daily
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | GFR 30-50 mL/min: 10 mg orally every 48 hours. GFR <30 mL/min or hemodialysis: 10 mg orally every 48 hours; not recommended for use in patients with GFR <30 mL/min due to lack of safety data. |
| Liver impairment | Child-Pugh Class A and B: no adjustment needed. Child-Pugh Class C: 10 mg orally every 48 hours; not recommended for use in patients with severe hepatic impairment due to lack of safety data. |
| Pediatric use | 2-5 years: 5 mg orally once daily. 6-11 years: 10 mg orally once daily. For children <2 years: safety and efficacy not established; dosing based on weight not available. |
| Geriatric use | No specific adjustment required. Use with caution due to potential for age-related renal impairment; consider starting at 10 mg orally every 48 hours if GFR <30 mL/min. |
| 1st trimester | Loratadine is generally considered safe in the first trimester; studies have not shown an increased risk of major birth defects. |
| 2nd trimester | No evidence of fetal harm in the second trimester; use if clearly needed. |
| 3rd trimester | Use with caution in the third trimester; may cause uterine contraction abnormalities at high doses. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S CLARITIN (CHILDREN'S CLARITIN).
| Placental transfer | Loratadine crosses the placenta; peak cord blood concentrations are about 25% of maternal plasma levels. |
| Breastfeeding | Loratadine is excreted into breast milk in small amounts; the estimated relative infant dose is about 1.1% of the maternal weight-adjusted dose. It is considered compatible with breastfeeding, but monitor the infant for drowsiness or irritability. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to loratadine or any component of the formulation
| Precautions | May cause drowsiness; use caution when driving or operating machinery. Avoid use with other antihistamines. Severe liver impairment may require dosage adjustment. Renal impairment (GFR <30 mL/min) may require dosage adjustment. |
| Food/Dietary | Grapefruit juice may slightly reduce loratadine absorption but not clinically significant. No other known food interactions. Can be taken with or without food. Avoid alcohol as it may increase drowsiness. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer; limited data suggest low risk) |
| Teratogenic Risk | Loratadine (Children's Claritin) is FDA Pregnancy Category B. Animal studies show no teratogenic effects. Human data from pregnancy registries and cohort studies do not indicate an increased risk of major birth defects, preterm birth, or low birth weight. However, first-trimester exposure data are limited. Avoid use in third trimester near term due to potential for neonatal withdrawal symptoms (irritability, tremors) reported with antihistamines. |
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond routine prenatal care. Monitor for maternal sedation or dizziness. For near-term use, observe neonate for signs of antihistamine withdrawal (jitteriness, irritability) for 48 hours after delivery. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies at high doses showed no impairment of fertility. Limited data; consider negligible effect on reproductive capacity. |
| Children's Claritin (loratadine) is a second-generation antihistamine with minimal sedative effects due to low CNS penetration. Onset of action is within 1-3 hours, duration ~24 hours. For seasonal allergies, start 2-4 weeks before pollen season. Use with caution in severe hepatic impairment (Child-Pugh >10): consider reduced dose or alternative. Not recommended for children <2 years due to lack of safety data. Can be given with or without food; food may slightly delay absorption but does not significantly affect efficacy. |
| Patient Advice | Give once daily at the same time. Do not exceed recommended dose. · May cause drowsiness in rare cases; observe child's reaction before activities requiring alertness. · Store at room temperature, away from moisture and heat. Keep out of reach of children. · For oral syrup, use the dosing syringe provided to measure exact dose. Shake bottle well before use. · If symptoms persist or worsen after 3 days, consult healthcare provider. · Do not use with other antihistamines or cold/flu products without doctor approval. |